CytoVale Inc. is developing a microfluidic platform to detect early signs of systemic inflammation before the onset of full-blown sepsis with the hope of enabling earlier and more successful treatment. The technology detects subtle changes in the shape and stiffness of white blood cells that presage acute inflammatory disease.

President and CEO Ajay Shah said the problem with current methods for detection of sepsis is that by the time serum biomarkers show up, it may be too late to change the course of disease.